ADMA Biologics Announces FDA Approval Of VanRx Fill-finish Machine; Stock Up

ADMA Biologics, Inc. (ADMA) announced FDA Approval for the company's in-house aseptic fill-finish machine, the VanRx SA25. The company said the VanRx approval provides ADMA with internal fill-finish operations, capable of sufficiently addressing all forecasted production requirements for commercial products. The approval will also provide the company with the opportunity to onboard new fill-finish contract manufacturing opportunities with third parties.

"With the VanRx operational, we are anticipating meaningfully improved gross margins, enhanced patient supply consistency, accelerated inventory production cycle times, and increased control and visibility of commercial product lot releases, creating more predictable near-term revenue results," said Adam Grossman, CEO of ADMA.

Shares of ADMA Biologics were up 11% in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT